Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

CoreAge Rx vs EverSlim

Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, EverSlim a 87. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

CoreAge Rx

#1 · Grade A+ · Best Value

Est. first month

$149/mo

Save ~89% vs brand-name
Get this deal Full CoreAge Rx review →
VS

EverSlim

#22 · Grade A- · Great Deal

Est. first month

$127/mo

Save ~91% vs brand-name
Get this deal Full EverSlim review →

The verdict

Better value: CoreAge Rx

CoreAge Rx takes it on Value Score, 93 to 87 an est. $149/mo first month, with no teaser step-up baked in. EverSlim isn't out of it: Shoppers who want budget-minded patients wanting flat-price compounded glp-1 care shipped nationwide.

CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealCoreAge RxEverSlim
Value Score93 (A+)87 (A-)
Est. first month$149/mo$127/mo
Save vs brand-name~89%~91%
Semaglutide$149/mo$127/mo
Tirzepatide$349/mo$183/mo
Both moleculesYesYes
PricingFlat — no step-upFlat — no step-up
CoverageAll 50 statesAll 50 states

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

88
Lowest Real Price
92
CoreAge Rx: 88. EverSlim: 92.
98
No Teaser-Rate Bait
90
CoreAge Rx: 98. EverSlim: 90.
98
Nationwide Availability
96
CoreAge Rx: 98. EverSlim: 96.
95
Both Molecules
92
CoreAge Rx: 95. EverSlim: 92.
95
Easy Cancellation
58
CoreAge Rx: 95. EverSlim: 58.
84
Reputation
82
CoreAge Rx: 84. EverSlim: 82.

CoreAge Rx

The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.

Why it's a deal

  • Flat, all-in monthly price with no intro-rate step-ups after month one
  • Both compounded semaglutide and tirzepatide on one account
  • Available in all 50 states
  • Straightforward, low-friction cancellation — no lock-in

The fine print

  • Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
  • No FDA-approved brand-name option (compounded only)
  • Does not yet publicly name its 503A/B pharmacy partner

EverSlim

EverSlim is a US telehealth program offering doctor-prescribed, compounded GLP-1 weight-loss medication delivered to your door.

Why it's a deal

  • Transparent flat pricing from 127 dollars a month for compounded semaglutide; medication, provider visit, and shipping included with no insurance.
  • Names its pharmacy partners (EPIQ Scripts, Foothills, Emerald) and DrTelx medical group; LegitScript-approved and NABP-accredited.
  • Available in all 50 states and DC, with asynchronous care in 44 states and live-visit access in the rest.
  • Offers both semaglutide and tirzepatide, plus care-team messaging between visits.

The fine print

  • Compounded medications are not FDA-approved, and no brand-name Wegovy, Ozempic, or Zepbound options are offered.
  • Site discloses that some imagery and content may be AI-generated and some ad figures are actors, not real clinicians.
  • Newer brand with limited independent, third-party review history.
Get the CoreAge Rx deal Get the EverSlim deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives board, and the same list for the other side is on alternatives to EverSlim.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.